Vermont-based CDMO, Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP Manufacturing

BURLINGTON, Vt.--()--Vernal Biosciences, an innovative mRNA and LNP Contract Development and Manufacturing Organization (“CDMO”) announced the completion of a $20MM funding round, led by Ampersand Capital Partners and Charles River Labs with participation from Dynamk Capital and the Vermont Center for Emerging Technologies.

The company will use the funding to complete its first state of the art GMP manufacturing facility, scheduled to be online July 2023, and support expanded manufacturing and capabilities in support of cGMP manufacturing.

CEO and Founder Christian Cobaugh is excited about the expansion of Vernal’s GMP capabilities, “We are on a mission to democratize mRNA R&D by making high purity mRNA and lipid nanoparticle (“LNP”) formulated mRNA readily available to more therapeutic innovators and biopharma leaders. This funding helps us make our vision a reality. In addition to expanding the capabilities of our research and preclinical business, we are wrapping up cGMP manufacturing readiness for our first site, which includes our process and analytical development capabilities to complement our platform technologies. The funding will also allow us to accelerate our second site, to begin next year, to support larger scale cGMP manufacturing for commercial mRNA drug products.”

Vernal offers full service manufacturing ranging from cell banking, plasmid DNA and the resulting mRNA, to formulations into a variety of lipid chemistries. Similar to their RUO operations, the GMP business leverages platform process and analytical technologies to rapidly manufacture high purity mRNA and LNP-formulated mRNA.

David Anderson, General Partner with Ampersand Capital added, “Ampersand is excited to continue our partnership with Christian and the Vernal team to support the Company’s ongoing transformation into a full-service CDMO in the mRNA end-market. Our recent experiences building advanced therapy CDMOs such as BrammerBio, ArrantaBio and Vibalogics, position Ampersand as an excellent partner for Vernal at this stage in the company’s growth.”

This funding comes on the heels of May 2022’s round of financing totalling $21MM, including investment from Vernal’s partner Alloy Therapeutics. There have been several other recent milestones in the company’s rapid growth. Vernal has scaled their workforce to 65 employees over the past year, added dozens of new customers, and increased scale by a factor of 20x.

For more information, contact CEO Christian Cobaugh at and 408.677.7802.

About Vernal Biosciences

Vernal Biosciences, founded in 2021 and headquartered just outside of Burlington, Vermont, is a fully integrated Contract Development and Manufacturing Organization (CDMO) with a singular focus on manufacturing and formulating mRNA and LNP-mRNA. Because science matters more than ever, Vernal is inspired to accelerate the potential of mRNA through democratizing access to our expertise and unparalleled mRNA and LNP-mRNA platform technologies. Combined with Good Manufacturing Practices (cGMP) and control and quality systems, Vernal’s technologies are an advanced manufacturing staging ground for research, preclinical, and ultimately clinical development supply needs.

Learn more at

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit or follow us on LinkedIn.


Christian Cobaugh, CEO

Social Media Profiles


Christian Cobaugh, CEO